Inhibition behavior of Sennoside A and Sennoside C on amyloid fibrillation of human lysozyme and its possible mechanism

Int J Biol Macromol. 2021 May 1:178:424-433. doi: 10.1016/j.ijbiomac.2021.02.213. Epub 2021 Mar 1.

Abstract

Amyloid proteins were recognized as the crucial cause of many senile diseases. In this study, the inhibitory effects of Sennoside A (SA) and Sennoside C (SC) on amyloid fibrillation were evaluated by the combination of biophysical approaches and molecular docking tool using human lysozyme (HL) as amyloid-forming model. The results of thioflavin-T (ThT), 8-anilino-1-naphthalenesulfonic acid (ANS) and congo red (CR) assays indicated that both SA and SC could inhibit the amyloid fibrillation of HL in a dose-dependent manner. The IC50 value of SA and SC on HL fibrillation was 200.09 μM and 186.20 μM, respectively. These findings were further verified by transmission electron microscopy (TEM) and atomic force microscopy (AFM), which showed that the addition of SA or SC could sharply reduce the amyloid fibrillation of HL. Additionally, the interactions of HL with SA and SC were investigated by steady-state fluorescence spectra and molecular docking studies. The results suggested that both SA and SC could bind to the binding pocket of HL and form a stable complex mainly via hydrogen bonds, van-der-Waals forces and hydrophobic interactions. In conclusion, our experiments revealed that both SA and SC can significantly inhibit amyloid fibrillation of HL.

Keywords: Amyloid fibrillation; Sennoside A; Sennoside C.

MeSH terms

  • Amyloid / chemistry*
  • Humans
  • Muramidase / chemistry*
  • Protein Aggregates*
  • Senna Extract / chemistry*
  • Sennosides / chemistry*

Substances

  • Amyloid
  • Protein Aggregates
  • Sennosides
  • Senna Extract
  • Muramidase
  • lysozyme C, human
  • sennoside C